Jing Wang

Antigen presentation requirements for effective cDC1-based cancer immunotherapy

This study shows that in vitro-derived cDC1s resemble tumor-infiltrating DCs and that MHC-I and MHC-II antigen presentation by these cells is essential for effective cancer immunotherapy.

YAP1 defines an emergent, plastic population of relapsed small cell lung cancer

This study identifies YAP1-positive cells in relapsed SCLC that exhibit drug tolerance and transition from SCLC to LCNEC-like features, losing some targets but gaining others.

NOTCH1 Acts as a Tumor Suppressor That Induces Early Differentiation in Head and Neck Cancer

This study clarifies that NOTCH1 acts as a tumor suppressor in head and neck cancer, reducing cancer stem cells and improving prognosis, despite conflicting prior reports.

PDK1 and YAP1/TEAD signaling drive acquired KRAS inhibitor resistance in KRAS-mutant non-small cell lung cancer.

This study identifies PDK1 and YAP1/TEAD signaling as drivers of acquired resistance to KRAS inhibitors in NSCLC and suggests their co-targeting as a potential therapeutic strategy.

CyTOF-based profiling of circulating tumor cells predicts aggressiveness and therapy response in SCLC liquid biopsies at a personalized level

This study uses CyTOF to profile circulating tumor cells in SCLC patients, identifying subtype-specific markers and treatment response correlations.

BRAFV600E-Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor Signaling

This study shows that BRAFV600E-driven lung cancer requires ERBB receptor signaling via ligand-mediated activation, and combined inhibition of BRAFV600E and ERBB improves therapeutic outcomes.

DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancer

This study identifies three distinct DDR phenotypes in SCLC associated with chemotherapy response and tumor evolution.

Acquired resistance to sotorasib in mutant NSCLC is vulnerable to PI3K-mTOR pathway inhibition mediated by 4E-BP1, a regulator of cap-dependent translation

This study identifies PI3K-mTOR pathway inhibition as a strategy to overcome acquired resistance to KRASG12C inhibitors in NSCLC by targeting 4E-BP1.

SMARCA4 mutation induces tumor cell-intrinsic defects in enhancer landscape and resistance to immunotherapy

This study shows that SMARCA4 mutations in lung cancer disrupt enhancer landscapes and innate immune gene expression, leading to immunotherapy resistance.

NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model

This study shows NPRL2 gene therapy reduces lung metastases in KRAS/STK11 mutant NSCLC in humanized mice by enhancing immune cell infiltration and reducing T cell inhibitory signals.

CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts

CombPDX evaluates drug synergism in PDX models using tumor growth curves and provides statistical metrics and inference procedures for combination effects.

Genomic and TCR Repertoire Intratumor Heterogeneity of Small-cell Lung Cancer and its Impact on Survival

This study examines genomic and TCR repertoire heterogeneity in SCLC, finding that lower TCR heterogeneity and mutational burden correlate with better survival.

Omics-Based Interaction Framework - a systems model to reveal molecular drivers of synergy

The paper introduces OBIF, a systems model that identifies molecular drivers of synergy by integrating statistical and biological interactions from omics data.